Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

0 search results for

Suggestions within Pfizer.com

Home
News
Press Releases

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

August 2025

08.05.2025
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

July 2025

07.25.2025
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
- Vaccines
- Vaccines
07.24.2025
Pfizer Completes Licensing Agreement with 3SBio
- Corporate
- Research and Pipeline
07.10.2025
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
- Research and Pipeline
- Medicines

June 2025

06.26.2025
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
- Prescription Medicines
- Medicines
06.25.2025
Pfizer Declares Third-Quarter 2025 Dividend
- Financial
- Finance
06.25.2025
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
- Financial
- Finance
06.02.2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance

May 2025

05.31.2025
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- Research and Pipeline
- Research
05.30.2025
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
05.22.2025
Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
- Research and Pipeline
- Medicines
05.19.2025
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
- Corporate
- Research and Pipeline

Page 1
Page 2
Current page 3
Page 4
Page 5

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

PfizerForAll
Healthcare Professionals
Grant Seekers
Business to Business

Privacy Statement
Accessibility Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube